Cinclus Pharma announces positive FDA interaction
Cinclus Pharma today announces that the company has completed a successful so-called end-of-phase-II meeting, with the US Food and Drug Administration (FDA) for the indication erosive gastroesophageal reflux disease (eGERD). The FDA broadly accepted Cinclus Pharma's proposal for the phase III program, including study design and primary endpoint for the studies. The positive outcome allows Cinclus Pharma to proceed with its phase III program.
Read more![Cinclus News Research 65255460](/media/vcpeg34w/cinclus-news-research-65255460.jpg?width=620&height=300&v=1d9df0f05072c80)